Teduglutide

Shop Teduglutide
Code ths10 applied at checkout

Also called: teduglutide

By The Health Stacks Research TeamUpdated September 17, 2026

Teduglutide is a man-made copy of a natural body chemical called GLP-2, a hormone made in the gut. It is a real medicine that has been approved for use in people.

It is given as a shot under the skin. It is used mostly by people with short bowel syndrome, a serious condition where a person has lost a large part of their intestine, often from surgery or disease.

These people often cannot get enough food and water on their own and need feeding through a vein, called parenteral nutrition.

ApprovedApproved by a regulator (e.g. FDA) for a specific medical use — the highest research-status tier. Verified confidence80–100 — backed by strong, well-corroborated sources (peer-reviewed research, clinical guidelines). Our highest confidence tier.

Benefits

What Teduglutide Helps With

The benefits people report — backed by research.

Gastrointestinal & gut (9)

Treatment of Short Bowel Syndrome 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 2 srcTeduglutide reduces need for parenteral support in short bowel syndrome with intestinal failure 92/100Rated 92/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Treatment of Irritable Bowel Syndrome with Constipation 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →GLP-2 is an intestinotrophic mediator / most important trophic hormone of the small intestine 88/100Rated 88/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Teduglutide used in treatment of pediatric short bowel syndrome 80/100Rated 80/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Teduglutide reduces parenteral nutrition volume and infusion time in short bowel syndrome 72/100Rated 72/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Growth hormone, glutamine, and optimal diet reduces parenteral nutrition in SBS patients 70/100Rated 70/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Intestinal adaptation over ~2 years via L-cell hormones; hormone analogs accelerate rehabilitation 68/100Rated 68/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Teduglutide can enable full transition to enteral autonomy 65/100Rated 65/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →

More reported benefits (11)

Treatment of Perianal Fistulizing Crohn's Disease 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Treatment of Crohn's Disease 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Treatment of Refractory Celiac Disease 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Treatment of Refractory Celiac Disease Type II 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →GLP-2 analogues enable reducing PN requirements in formerly PN-dependent patients 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Clonidine reduces diarrhea and sodium loss in patients with proximal jejunostomy 72/100Rated 72/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Anti-inflammatory 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Immune modulation 90/100Rated 90/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →GLP-2 analog use reduces PN-related risks and improves quality of life and prognosis 65/100Rated 65/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Teduglutide is a recombinant 33-amino acid GLP-2 analogue promoting intestinal growth in short bowel syndrome 60/100Rated 60/100Source typeSpecialist communityIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →Teduglutide is a recombinant GLP-2 analogue used for short bowel syndrome via promoting intestinal growth 60/100Rated 60/100Source typeSpecialist communityIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →

Free: The Peptide Stack Cheat-Sheet

You just read the research on Teduglutide. The cheat-sheet maps the most-used peptide stacks — doses, timing, and what to check before buying — on one page.

No spam. Unsubscribe anytime.

How People Use It

1 reported routine — each line links to the source it came from.

Self-reported & vendor-suggested

Routines shared by users and sellers in forums and product pages — anecdotal, not tested in clinical trials. We show them for completeness, not as a recommendation.

SubQ

  • Subcutaneous injection 60/100Rated 60/100Source typeSpecialist communityIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ source

mg vs mcg: one milligram (mg) equals 1,000 micrograms (mcg) — multiply by 1,000 going from mg to mcg, divide by 1,000 going from mcg to mg. Mixing the two up is a thousand-fold dosing error: 1 mg taken instead of 1 mcg is a 1,000× overdose; 1 mcg instead of 1 mg is a 1,000× underdose. Always double-check the unit label and the decimal place.

Safety

Known Side Effects

Adverse effects reported in the research and by community use.

  • Serious Adverse EventsSevere 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ source
  • Potential toxicity of parenteral vitamin preparationsModerate 70/100Rated 70/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ doi.org

Reported in research and community sources — not exhaustive. Discontinue use and consult a healthcare professional if side effects occur.

Get Teduglutide

Compare research-grade suppliers with third-party COAs and published purity data. For in-vitro and laboratory research use only — not for human consumption, diagnosis, or treatment.

Shop Teduglutide
Code ths10 applied at checkout

Evidence

Research Citations (2)

Every claim above traces back to a source you can check — here are 2 of them.

  • Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome.

    95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
    Source

  • Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure

    95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
    Source

News

Latest on Teduglutide

Dated, sourced reporting that mentions Teduglutide.

ResearchJun 20, 2016

Short bowel syndrome management reviewed: where teduglutide fits

An updated review in Current Gastroenterology Reports (July 2016, Carroll and Benedetti) walks the complications and management ladder of short bowel syndrome - from diet and antisecretory drugs to growth factors - and places teduglutide as the enteral-trophic option for patients still dependent on IV nutrition.

95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →Read →
Clinical

STEP trial: teduglutide reduces IV nutrition in short bowel syndrome

The STEP trial (Gut, July 2011, Jeppesen et al.) randomized short-bowel patients to teduglutide - a GLP-2 analog - or placebo and showed a meaningful share of treated patients reduced or ended parenteral nutrition and fluid support, the result that underpinned the medicine's approvals (Gattex/Revestive) for intestinal failure.

95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →Read →
Clinical

Six-Month Safety and Effectiveness of Teduglutide in Patients with Short Bowel Syndrome in Japan: Interim Analysis of Post-marketing Surveillance

This interim analysis of a 36-month post-marketing surveillance program reports real-world safety and effectiveness of teduglutide in 92 adults and children with short bowel syndrome in Japan (all patients who started treatment August 2021-August 2022). At 6 months, the overall mean change in parenteral nutrition dose was about -2402 mL/week, and 42.4% of patients (39/92) achieved at least a 20% reduction in parenteral-support volume. The paper notes teduglutide was approved in the USA and Europe in 2012 and in Japan in 2021 as the first GLP-2 analogue promoting intestinal adaptation.

95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →Read →
Regulatory

U.S. FDA Approves GATTEX (teduglutide) for Children 1 Year of Age and Older With Short Bowel Syndrome (SBS)

Takeda announced that FDA approved extending the GATTEX (teduglutide) indication to pediatric patients 1 year of age and older with short bowel syndrome who depend on parenteral support. The approval was supported by a 24-week pediatric study (NCT02682381) in 59 patients aged 1-17. In the study, 69% (18/26) of patients on GATTEX 0.05 mg/kg/day reduced parenteral-support volume by 20% or more, and 3 of 26 (12%) weaned off parenteral support entirely.

40/100Rated 40/100Source typeVendor / seller pageIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →Read →

Wondering how Teduglutide pricing compares across suppliers? Our original market data shows the full picture.

See the State of the Peptide Market 2026 →

Free: The Peptide Stack Cheat-Sheet

The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.

No spam. Unsubscribe anytime.